```html

Coccidioidomycosis (Valley Fever)

What is Coccidioidomycosis (Valley Fever)?

Coccidioidomycosis, commonly known as “Valley Fever,” is a fungal infection caused by inhaling spores of the Coccidioides species (primarily C. immitis and C. posadasii). These molds live in the soil of arid and semi‑arid regions of the Americas, especially the southwestern United States, parts of Mexico, Central and South America. When the soil is disturbed—by wind, construction, farming, or even normal desert breezes—tiny spores become airborne. Once inhaled, the spores can settle in the lungs and, in some people, spread to other body sites.

Most healthy adults who inhale the spores develop either no symptoms or a mild, flu‑like illness that resolves on its own. However, certain groups—such as older adults, people with weakened immune systems, or those with chronic lung disease—are at higher risk for severe or disseminated disease.

The condition is not transmitted from person to person; infection occurs only through exposure to contaminated soil or dust.

Common Causes

While the underlying cause is the same fungus, several specific situations increase the likelihood of exposure:

• Living or working in endemic regions (Arizona, California’s Central Valley, Nevada, New Mexico, Texas, Utah).
• Construction, demolition, or excavation that disturbs contaminated soil.
• Agricultural activities such as plowing, harvesting, or livestock handling.
• Military training exercises or other outdoor drills in desert environments.
• Recreational activities that stir up dust—e.g., hiking, off‑road vehicle riding, camping.
• Dust storms (haboobs) that carry spores across large distances.
• Home renovation projects that involve digging or moving large amounts of soil.
• Occupational exposure for farmworkers, archeologists, or geologists.
• Travel to endemic areas without prior immunity.
• Extreme weather events (e.g., drought followed by heavy rains) that promote fungal growth.

Associated Symptoms

Symptoms usually appear 1–3 weeks after exposure, but the timing can vary. They fall into three broad categories:

1. Mild, flu‑like illness (most common)

• Fever (often 100–103°F / 37.8–39.4°C)
• Dry cough
• Chest pain or tightness
• Fatigue and malaise
• Headache
• Muscle or joint aches
• Sore throat
• Weight loss (if illness persists)

2. Pulmonary complications

• Persistent cough that may produce sputum
• Shortness of breath
• Chest X‑ray showing infiltrates, nodules, or cavities
• Bronchitis‑like picture lasting weeks to months

3. Disseminated disease (rare, ~1% of cases)

• Skin lesions: raised, painless nodules that may ulcerate
• Joint pain or swelling (arthritis)
• Bone pain (osteomyelitis)
• Central nervous system involvement: severe headache, stiff neck, confusion, or seizures (meningitis)
• Enlarged lymph nodes
• Fatigue and night sweats similar to tuberculosis

Symptoms can overlap with other respiratory infections, which is why specific testing is necessary for an accurate diagnosis.

When to See a Doctor

Most people recover without medical care, but you should contact a healthcare professional if you experience any of the following:

• Fever lasting more than 5 days or a temperature ≥ 101.5°F (38.6°C) that does not improve.
• Persistent cough, chest pain, or shortness of breath that worsens after a week.
• Rash or skin lesions that develop after a respiratory illness.
• Joint or bone pain that is severe or progressively worsening.
• Neurologic symptoms—headache, confusion, vision changes, or stiff neck.
• Any symptoms in a person with a weakened immune system (e.g., HIV, organ transplant, chemotherapy).
• Symptoms that do not improve after a week of rest, hydration, and over‑the‑counter fever reducers.

Diagnosis

Diagnosing Valley Fever involves a combination of clinical assessment, laboratory testing, and imaging.

1. Medical history and physical exam

• Doctor asks about travel or residence in endemic areas, recent dust exposure, and underlying health conditions.
• Physical exam focuses on lungs, skin, joints, and neurological status.

2. Laboratory tests

• Serologic testing (IgM and IgG antibodies) – Detects immune response; IgM appears early, IgG later and persists.
• Complement fixation (CF) titer – Higher titers suggest more severe or disseminated disease.
• Enzyme immunoassay (EIA) – Rapid screening for antibodies.
• Polymerase chain reaction (PCR) – Detects fungal DNA in respiratory specimens (available in reference labs).
• Culture – Rarely performed because the organism is hazardous to lab staff; requires biosafety level 3.
• Complete blood count (CBC) – May show mild leukocytosis or eosinophilia.

3. Imaging

• Chest X‑ray – Shows infiltrates, nodules, or cavities in the lungs.
• CT scan of the chest – More detailed; helps assess extent of pulmonary involvement.
• For disseminated disease, MRI or CT of the brain/spine may be ordered.

4. Skin test (historical)

Skin testing with coccidioidin or spherulin was once used to assess prior exposure, but it is no longer recommended for diagnosing active infection.

Treatment Options

Treatment decisions depend on disease severity, patient age, immune status, and whether the infection has spread beyond the lungs.

1. Mild, self‑limited disease

• Most healthy adults: No antifungal medication required.
• Supportive care: rest, hydration, antipyretics (acetaminophen or ibuprofen), and cough suppressants as needed.
• Follow‑up: Repeat serology in 2–3 weeks to ensure antibody levels are falling.

2. Moderate to severe pulmonary disease

• Azoles – First‑line oral antifungals:
  • Fluconazole 400–800 mg daily
  • Itraconazole 200 mg twice daily (if fluconazole not tolerated)
• Therapy typically lasts 3–6 months; longer courses may be needed for persistent symptoms.
• Monitor liver function tests (LFTs) every 2–4 weeks because azoles can cause hepatotoxicity.

3. Disseminated or central nervous system (CNS) disease

• Amphotericin B (liposomal formulation) – Administered intravenously for severe cases or CNS involvement.
• After initial amphotericin, transition to long‑term oral azole (usually fluconazole 800 mg daily) for at least 12 months, often lifelong for CNS disease.
• Adjunctive therapy: corticosteroids may be used for severe inflammatory lung disease, but only under specialist guidance.

4. Supportive home measures

• Stay well‑hydrated and maintain a balanced diet to support immune function.
• Avoid smoking and exposure to second‑hand smoke, which irritates the lungs.
• Use a humidifier if indoor air is very dry (dry air can exacerbate cough).
• Over‑the‑counter pain relievers for joint or muscle aches, respecting dosing limits.

5. Follow‑up care

• Serial serology (IgG titers) every 3–6 months for the first year.
• Repeat chest imaging if symptoms persist or recur.
• For disseminated disease, periodic ophthalmologic and neurologic examinations.

Prevention Tips

Because Valley Fever is caused by an environmental fungus, complete avoidance is impossible in endemic areas, but risk can be reduced:

• Stay informed about local outbreak alerts from public‑health agencies (CDC, state health departments).
• Minimize dust exposure when working outdoors:
  • Wet soil before digging or planting.
  • Wear a NIOSH‑approved N95 respirator or a half‑face mask with a P100 filter.
  • Use wind‑breaks or perform work on calm days.
• Protect vulnerable individuals (elderly, immunocompromised) by limiting their time outdoors during dust‑raising activities.
• Keep windows and doors closed during dust storms; use air filtration units with HEPA filters.
• For construction sites, follow Occupational Safety and Health Administration (OSHA) guidelines for respiratory protection.
• Maintain good overall health—balanced diet, regular exercise, adequate sleep—to support immune defenses.
• If you travel to an endemic region, plan outdoor activities for early morning or late afternoon when spore concentrations are lower.

Emergency Warning Signs

Key Take‑aways

• Coccidioidomycosis (Valley Fever) is a fungal infection acquired by inhaling spores from contaminated soil.
• Most healthy adults experience a mild, self‑limited illness, but the disease can become severe or spread to other organs, especially in people with weakened immune systems.
• Symptoms range from flu‑like fever and cough to skin lesions, joint pain, and, in rare cases, meningitis.
• Diagnosis relies on serologic testing, imaging, and, when necessary, molecular methods.
• Treatment is observation for mild disease; oral azoles for moderate disease; and intravenous amphotericin B followed by long‑term azoles for disseminated or CNS infection.
• Prevent exposure by reducing dust inhalation, using respiratory protection, and staying informed about local outbreaks.
• Seek emergency care promptly for severe respiratory or neurologic symptoms.

---

Sources: Mayo Clinic, Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH) – National Institute of Allergy and Infectious Diseases, World Health Organization (WHO), Cleveland Clinic, and peer‑reviewed articles in *Clinical Infectious Diseases* and *The New England Journal of Medicine* (2020‑2024).

```